Table 1 Demographic and clinical characteristics of all patients.

From: Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease

Characteristics

Total (n = 101)

Nemonoxacin group (n = 50)

Moxifloxacin group (n = 51)

p value

Age, years*

64.12 ± 7.51

65.08 ± 8.19

63.18 ± 6.73

0.385

Male

97 (96.0)

49 (98.0)

48 (94.1)

0.317

BMI, kg/m2 *

21.68 ± 3.47

21.40 ± 3.60

21.95 ± 3.35

0.408

Educational level

0.864

 Primary and below

33 (32.7)

16 (32.0)

17 (33.3)

 

 Secondary

40 (39.6)

21 (42.0)

19 (37.3)

 

 High school

17 (16.8)

7 (14.0)

10 (19.6)

 

 University and above

11 (10.9)

6 (12.0)

5 (9.8)

 

History of smoking

0.722

 Current smoker

40 (39.6)

18 (36.0)

22 (43.1)

 

 Ex-smoker

51 (50.5)

28 (56.0)

23 (45.1)

 

 Never smoker

10 (9.9)

4 (8.0)

6 (11.8)

 

Duration of antibiotic therapy, days

6.00 (6.00–9.00)

6.00 (6.00–9.00)

6.00 (6.00–6.00)

0.142

AEs in the previous year

1.00 (0.00–2.00)

1.00 (0.00–2.00)

1.00 (0.00–2.00)

0.344

CAT score*

20.16 ± 5.02

20.71 ± 5.81

19.60 ± 4.07

0.297

BDI total score

7.00 (5.00–8.00)

6.00 (5.00–8.00)

7.00 (4.75–9.00)

0.189

Lung function

 Post-BD FEV1 (% pred)

47.60 (37.17–58.40)

43.70 (34.27–55.80)

48.55 (37.85–59.50)

0.307

 Post-BD FEV1/FVC (%)

43.23 (34.00–49.07)

42.73 (34.76–47.84)

43.61 (34.00–51.32)

0.643

Inhalers

0.467

 LAMA

6 (5.9)

2 (4.0)

4 (7.8)

 

 ICS + LABA

6 (5.9)

2 (4.0)

4 (7.8)

 

 LABA + LAMA

34 (33.7)

20 (40.0)

14 (27.5)

 

 ICS + LABA + LAMA

55 (54.5)

26 (52.0)

29 (56.9)

 

Comorbidities

 Hypertension

34 (33.7)

20 (40.0)

14 (27.5)

0.216

 Diabetes mellitus

6 (5.9)

3 (6.0)

3 (5.9)

1.000

 Cardiovascular disease

16 (15.8)

9 (18.0)

7 (13.7)

0.589

 Chronic heart failure

3 (3.0)

1 (2.0)

2 (3.9)

1.000

 Myocardial infarction

1 (1.0)

1 (2.0)

0 (0.0)

1.000

 Peripheral arterial disease

2 (2.0)

1 (2.0)

1 (2.0)

1.000

 Chronic kidney disease

6 (5.9)

3 (6.0)

3 (5.9)

1.000

  1. Data are presented as n (%) or median (IQR) unless otherwise stated. *Data are presented as the mean (SD).
  2. AECOPD acute exacerbations of chronic obstructive pulmonary disease, BMI body mass index, AEs acute exacerbations, LAMA long-acting muscarinic receptor antagonist, ICS inhaled corticosteroids, LABA long-acting beta-adrenoceptor agonist, CAT COPD Assessment Test, mMRC modified Medical Research Council, BDI baseline dyspnea index, GOLD global initiative for chronic obstructive lung disease, BD bronchodilator, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity.
Back to article page